14th mars 2023
Actualités
Retrouvez tous nos derniers communiqués de presse. Restez informé des dernières actualités et des événements auxquels participe Curium.
2nd mars 2023
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
27th janvier 2023
Curium is attending these global congresses in 2023
21st décembre 2022
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
24th novembre 2022
Curium’s Customers to benefit from Mo-99 Production restart
22nd novembre 2022
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
9th novembre 2022
Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
18th août 2022
NRG and Curium Sign Multi-Year Isotope Production Contract
27th juin 2022
Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency
12th mai 2022
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
3rd mai 2022
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
19th avril 2022
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
5th avril 2022
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
25th janvier 2022
Curium to become major player in the supply on non carrier added Lu-177
15th décembre 2021
Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer
27th octobre 2021
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
24th août 2021
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
1st juin 2021
Curium Acquires Austrian Radiopharmaceuticals Company IASON
5th mai 2021
RadioMedix & Curium Announce Detectnet™ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
4th mai 2021